ADRB2 and lymphoma: Notably, β2AR signaling has been implicated in the progression of multiple cancers[15, 17, 40, 56, 57, 58, 59], and our work now extends this paradigm to EBV+ DLBCL‐representing the first evidence of nerve‐driven tumor progression in lymphoma.